IBM
Affymetrix
Bioaccerlerate
Invitrogen

 

IBM Healthcare and Life Sciences exists to enable our clients to transform the development and delivery of safer, more affordable and more effective healthcare, diagnostics, and drugs, through deep industry insight and the application of information technology. From data analysis to clinical trial management to medical imaging and diagnostics, IBM and its global network of Business Partners can provide end-to-end solutions and services to help you integrate disparate data sources, automate and streamline research and business processes, share information and collaborate on findings, and facilitate regulatory compliance. Combining IBM's core strength in providing robust information technology, middleware, and services, IBM Healthcare and Life Sciences delivers innovative, scalable infrastructure solutions that are unique to the industry.

For more information, please visit www.ibm.com/industries/healthcare.

 

 

Affymetrix is proud to support BioBank Central and FasterCures in promoting collaboration, education and communication across the biobanking community. We believe that effectively leveraging biospecimens in life sciences research is central to improving quality of life and patient care. 

Since 1991, Affymetrix has been a pioneer in creating breakthrough microarray tools to elucidate the underlying genomic factors of disease and therapeutic response. Our customers include pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes. Affymetrix offers a portfolio of integrated products and services to address growing markets focused on understanding the relationship between genes and human health.  

GeneChip® DNA Analysis products provide scientists with a powerful tool for translating the human genome sequence into a functional understanding of human health and disease. GeneChip DNA Analysis arrays can be used in whole genome scans for copy number, SNP discovery, disease association and linkage studies. The flexible platform also enables researchers to cost effectively target sequence and SNP analysis to their regions of interest. 

The expanding line of GeneChip® Expression products can be used to measure expression at the gene-, exon-, and transcript-level. Through novel assays, these innovative tools are deepening researchers' understanding of the impact of cellular pathways, alternative splicing, gene regulation and epigenetics on disease. 

And as the only microarray platform that is FDA 510K approved and CE marked for in vitro diagnostic use, Affymetrix also provides a pathway for translating discoveries into clinical use through the Powered by Affymetrix™ partnership program.

Visit us today at www.affymetrix.com.      

 

 

Bioaccelerate Holdings Inc. is a pharmaceutical development organization ("PDO") that seeks to acquire, develop and commercialize novel pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate uses its broad network of academic, industry and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease and anti-infectives.

For more information, visit www.bioaccelerate.com.

 

 

Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition--providing essential life science technologies for disease research, drug discovery, and commercial bioproduction. The company's technology also supports emerging areas of research, such as regenerative medicine, diagnostics and nanotechnology--placing Invitrogen's products in nearly every major laboratory in the world. As a part of its global corporate citizenship initiative, the company also supports organizations in each of its communities dedicated to science education and environmental sustainability. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005.

For more information, visit www.invitrogen.com.